What is HC Wainwright's Estimate for AURA FY2028 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Aura Biosciences in a research note issued to investors on Wednesday, May 28th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($1.60) for the year. HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' FY2029 earnings at ($1.17) EPS.

Several other analysts have also recently weighed in on AURA. Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Finally, JMP Securities reissued a "market outperform" rating and set a $19.00 price target on shares of Aura Biosciences in a report on Friday, May 23rd. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $22.00.

Aura Biosciences Stock Performance

NASDAQ:AURA traded down $0.25 during mid-day trading on Thursday, hitting $5.84. 266,431 shares of the stock were exchanged, compared to its average volume of 206,590. The stock has a market capitalization of $293.57 million, a price-to-earnings ratio of -3.38 and a beta of 0.43. The firm's 50-day simple moving average is $5.63 and its 200 day simple moving average is $7.24. Aura Biosciences has a fifty-two week low of $4.35 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.08).

Hedge Funds Weigh In On Aura Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC increased its stake in shares of Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock valued at $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after purchasing an additional 783,984 shares during the last quarter. Acorn Capital Advisors LLC bought a new position in shares of Aura Biosciences in the 1st quarter valued at $3,460,000. B Group Inc. bought a new position in shares of Aura Biosciences in the 4th quarter valued at $3,885,000. Finally, Regency Capital Management Inc. DE increased its stake in shares of Aura Biosciences by 23.0% in the 1st quarter. Regency Capital Management Inc. DE now owns 749,482 shares of the company's stock valued at $4,392,000 after purchasing an additional 140,058 shares during the last quarter. Institutional investors own 96.75% of the company's stock.

Insiders Place Their Bets

In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total transaction of $39,319.38. Following the transaction, the insider now owns 179,313 shares in the company, valued at $984,428.37. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony S. Gibney acquired 50,000 shares of the stock in a transaction on Friday, May 16th. The shares were bought at an average price of $4.90 per share, for a total transaction of $245,000.00. Following the purchase, the insider now owns 58,452 shares in the company, valued at approximately $286,414.80. This trade represents a 591.58% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 9,578 shares of company stock worth $52,067 in the last 90 days. Company insiders own 5.40% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.